Pharma & HealthcareTop Companies
Pharma & Healthcare

Top Bio Preservation Market Companies - Rankings, Profiles, Market Share, SWOT & Strategic Outlook

Industry

Pharma & Healthcare

Published

Feb 2026

Share:

Pharma & Healthcare

Top Bio Preservation Market Companies - Rankings, Profiles, Market Share, SWOT & Strategic Outlook

$3,590

Choose License Type

Only one user can use this report

Additional users can access this report

You can share within your company

Company Contents

Quick Facts & Snapshot

2025 Market Size (US$)
1.63 Billion
2026 Forecast (US$)
1.77 Billion
2032 Forecast (US$)
2.93 Billion
CAGR (2025-2032)
8.70%

Summary

The Bio Preservation market is entering a robust expansion phase as biobanks, cell therapy developers, and diagnostic labs scale globally. Safety, regulatory compliance, and cold-chain reliability are driving premium demand, allowing leading Bio Preservation market companies to consolidate share. With the market rising from US$ 1.63 Billion in 2025 to US$ 2.93 Billion by 2032, an 8.70% CAGR will reward innovation-led players.

2025 Revenue of Top Bio Preservation Suppliers
ReportMines Logo

Source: Secondary Information and ReportMines Research Team - 2026

Ranking Methodology

Rankings of Bio Preservation market companies are based on a composite score combining quantitative and qualitative indicators. Core metrics include 2025 Bio Preservation revenue, multi-year revenue trajectory, and share of high-growth segments such as cell therapy and biobanking. We also assess contract wins with leading pharma, CROs, and hospital networks, installed base of freezers and cryogenic systems, and breadth of consumables and media portfolios. Technology differentiation, IP strength, and integration of digital monitoring, automation, and quality-control features are weighted alongside after-sales service coverage and global cold-chain support. Each company receives a normalized score across revenue scale, growth, innovation, geographic reach, and customer stickiness. The final ranking reflects balanced performance rather than size alone, highlighting Bio Preservation market companies that combine commercial strength with sustainable competitive advantages.

Top 10 Companies in Bio Preservation

1
Thermo Fisher Scientific Inc.
Biobanking, cell and gene therapy, clinical diagnostics cold storage.
Global leader in integrated bio-preservation instruments, consumables, and monitoring solutions.
Ultra-low temperature freezers, cryogenic storage, controlled-rate freezers, temperature monitoring software.
Pharma majors, national biobanks, large academic medical centers.
Strongest presence in North America and Europe; rapidly growing footprint in Asia Pacific.
USA
Expanded contract manufacturing for cell therapies; launched cloud-connected ULT platforms; selective acquisitions in sample management software.
US$ 430.00 Million
2
Merck KGaA (MilliporeSigma)
Cell therapy, gene therapy, bioprocessing cold chain.
Top-tier provider of preservation media, reagents, and integrated solutions for advanced therapies.
Cryopreservation media, stabilizing reagents, single-use containers, quality-control analytics.
Biotech innovators, CDMOs, research institutes.
Strong in Europe and North America; targeted expansion in China and India.
Germany
Invested in new preservation media plant; partnered with CDMOs on closed-system workflows.
US$ 360.00 Million
3
Becton, Dickinson and Company (BD)
Blood banking, clinical labs, infectious disease diagnostics.
Major player in sample collection, storage, and transport systems supporting clinical and research workflows.
Vacutainers, transport media, cold-chain packaging, track-and-trace systems.
Hospitals, diagnostic labs, blood banks.
Broad global reach with strong penetration in North America, Europe, and emerging markets.
USA
Rolled out integrated sample integrity platforms; expanded automation-ready consumables.
US$ 295.00 Million
4
BioLife Solutions, Inc.
Cell therapy developers, regenerative medicine biotechs.
Specialist provider focused on cell and gene therapy preservation media and cold-chain solutions.
cGMP cryopreservation media, vial and bag storage systems, shipping containers.
Cell therapy biotech firms, academic centers, CDMOs.
Strong in North America, expanding in Europe and Asia Pacific CGT clusters.
USA
Deepened partnerships with CGT firms; optimized portfolio after divestitures to refocus on core bio-preservation.
US$ 210.00 Million
5
Chart Industries, Inc. (MVE Biological Solutions)
Biobanks, IVF clinics, cell repositories.
Leading supplier of cryogenic storage tanks and freezers for large-scale biobanking.
Liquid nitrogen freezers, automated cryogenic storage, bulk LN2 systems.
Public and private biobanks, fertility clinics, pharma repositories.
Strong in North America and Europe; building installations in Asia and Latin America.
USA
Introduced energy-efficient cryogenic platforms; expanded service footprint in Asia.
US$ 185.00 Million
6
Haier Biomedical Co., Ltd.
Hospitals, disease control centers, regional biobanks.
Cost-competitive manufacturer of biomedical freezers and cold storage equipment.
Ultra-low freezers, blood bank refrigerators, vaccine storage units.
Public health agencies, hospitals, research labs.
Dominant in China; strong growth in Asia, Africa, and Latin America.
China
Aggressive export strategy; launched smart IoT-connected freezers targeting emerging markets.
US$ 170.00 Million
7
PHC Holdings Corporation (PHCbi)
Academic research, pharma R&D, clinical labs.
Premium provider of lab freezers and incubators for high-end research.
Energy-efficient ULT freezers, CO2 incubators, monitoring solutions.
Universities, pharma research labs, hospital labs.
Strong in Japan and Europe; niche premium position in North America.
Japan
Strengthened distributor networks; launched low-noise, low-energy ULT models.
US$ 155.00 Million
8
Helmer Scientific Inc.
Blood centers, hospital pharmacies, clinical laboratories.
Specialist in medical-grade refrigeration for blood and clinical products.
Blood bank refrigerators, plasma freezers, controlled room temperature storage.
Blood banks, health systems, reference labs.
Strong presence in North America; selective distribution in Europe and Latin America.
USA
Enhanced regulatory-compliant designs; deepened OEM partnerships with hospital system integrators.
US$ 95.00 Million
9
Cryoport, Inc.
Cell and gene therapy logistics, clinical trial supply.
Niche leader in temperature-controlled logistics for advanced therapies.
Cryogenic shipping containers, real-time tracking, logistics orchestration platforms.
Biopharma companies, CGT developers, CROs.
Global network with strong North America-Europe corridors and growing Asia Pacific presence.
USA
Expanded lane coverage in Europe and Asia; integrated advanced monitoring analytics.
US$ 88.00 Million
10
Brooks Automation (Brooks Life Sciences / Azenta, Inc.)
Automated biobanks, pharma discovery, population genomics.
Automation-focused provider of sample storage and biobanking solutions.
Automated storage systems, sample management software, robotic handling.
Pharma, large biobanks, genomics consortia.
Strong in North America and Europe; selective flagship projects in Asia Pacific.
USA
Scaled automation-as-a-service offerings; targeted national genomic programs.
US$ 82.00 Million

Source: Secondary Information and ReportMines Research Team - 2026

Detailed Company Profiles

1

Thermo Fisher Scientific Inc.

Global life-science tools leader providing end-to-end bio-preservation equipment, consumables, and monitoring platforms for research, clinical, and biopharma customers.

Key Financials: 2025 Bio Preservation revenue US$ 430.00 Million; estimated segment growth 9.20% annually 2025-2032.
Flagship Products: TSX ULT Freezers, CryoPlus Storage Systems, Smart-Vue Pro Monitoring
2025-2026 Actions: Expanded CGT-focused cold-chain portfolio, integrated cloud monitoring, and acquired niche sample-management software vendor.
Three-line SWOT: Broadest global installed base and brand trust; Complex portfolio can slow decision-making; Opportunity—scaling advanced therapies and large biobank projects worldwide.
Notable Customers: Pfizer, UK Biobank, Mayo Clinic
2

Merck KGaA (MilliporeSigma)

Science and technology company offering high-value preservation media and reagents supporting bioprocessing, cell therapy, and genomic applications.

Key Financials: 2025 Bio Preservation revenue US$ 360.00 Million; R&D intensity approximately 12.50% of segment revenue.
Flagship Products: Cryo-Sure Media, BioCelerate Stabilizers, Mobius Single-Use Systems
2025-2026 Actions: Commissioned new media plant in Europe, co-developed closed-system workflows with leading CDMOs, and expanded regulatory support services.
Three-line SWOT: Strong biochemical and formulation expertise; Limited ownership of large hardware installed base; Opportunity—bundling media with single-use systems for CGT scale-up.
Notable Customers: Lonza, Novartis, Dana-Farber Cancer Institute
3

Becton, Dickinson and Company (BD)

Diversified medical technology company with strong presence in sample collection, stabilization, and transport products for diagnostics and research.

Key Financials: 2025 Bio Preservation revenue US$ 295.00 Million; operating margin around 17.40% in the segment.
Flagship Products: BD Vacutainer, BD Microtainer, BD Specimen Transport Systems
2025-2026 Actions: Launched integrated pre-analytical integrity platforms and expanded automation-compatible tubes for high-throughput labs.
Three-line SWOT: Unmatched distribution in clinical settings; Lower exposure to high-growth CGT segment; Opportunity—leveraging hospital footprint to upsell advanced preservation solutions.
Notable Customers: Quest Diagnostics, Red Cross Blood Services, NHS Hospitals
4

BioLife Solutions, Inc.

Specialist biotechnology company providing preservation media and storage systems tailored to cell and gene therapy developers.

Key Financials: 2025 Bio Preservation revenue US$ 210.00 Million; segment CAGR projected at 11.80% through 2032.
Flagship Products: CryoStor, HypoThermosol, evo Cold-Chain Containers
2025-2026 Actions: Rationalized portfolio to focus on CGT preservation, expanded key accounts with late-stage therapy sponsors, and optimized operations.
Three-line SWOT: Deep CGT domain expertise and high switching costs; Narrower diversification versus conglomerates; Opportunity—rising approvals of commercial CGT products globally.
Notable Customers: Bluebird bio, Kite Pharma, Fred Hutchinson Cancer Center
5

Chart Industries, Inc. (MVE Biological Solutions)

Industrial engineering company delivering cryogenic storage equipment and systems for large-scale biological sample preservation.

Key Financials: 2025 Bio Preservation revenue US$ 185.00 Million; backlog growth around 8.30% year-on-year.
Flagship Products: MVE Cryogenic Freezers, Fusion Freezer Systems, Bulk LN2 Storage Tanks
2025-2026 Actions: Introduced energy-optimized cryogenic lines, expanded service contracts, and partnered with national biobanks for mega-storage projects.
Three-line SWOT: Highly reliable cryogenic engineering and large installed base; Dependent on capital expenditure cycles; Opportunity—population biobanking and large genomics repositories.
Notable Customers: National Institutes of Health, China Kadoorie Biobank, Major IVF Networks
6

Haier Biomedical Co., Ltd.

China-based manufacturer offering broad ranges of biomedical freezers and refrigerators targeted at hospitals and public health agencies.

Key Financials: 2025 Bio Preservation revenue US$ 170.00 Million; strong emerging-market growth above 10.00% annually.
Flagship Products: DW Series ULT Freezers, Blood Bank Refrigerators, Vaccine Storage Cabinets
2025-2026 Actions: Pushed export-led strategy, launched IoT-enabled models with remote monitoring, and secured tenders in Africa and Southeast Asia.
Three-line SWOT: Competitive pricing and local manufacturing scale; Perception gap in premium research segment; Opportunity—public health investments and donor-funded lab upgrades.
Notable Customers: CDC China, African Public Health Labs, Regional Hospital Networks
7

PHC Holdings Corporation (PHCbi)

Japanese provider of high-performance laboratory equipment emphasizing reliability and energy efficiency for research environments.

Key Financials: 2025 Bio Preservation revenue US$ 155.00 Million; operating margin approximately 15.10%.
Flagship Products: VIP ECO ULT Freezers, MIR Incubators, LabAlert Monitoring
2025-2026 Actions: Released next-generation low-energy ULT series, strengthened academic partnerships, and enhanced EU and US distribution alliances.
Three-line SWOT: Strong technology reputation and low failure rates; Smaller marketing footprint than global giants; Opportunity—sustainability-driven equipment upgrades in mature markets.
Notable Customers: University of Tokyo, Roche Research Sites, European Academic Consortia
8

Helmer Scientific Inc.

Privately held company specializing in medical-grade refrigeration for blood management and clinical product preservation.

Key Financials: 2025 Bio Preservation revenue US$ 95.00 Million; steady mid-single-digit growth at 6.40% annually.
Flagship Products: Blood Bank Refrigerators, Plasma Freezers, Pharmacy Refrigerators
2025-2026 Actions: Enhanced compliance-focused product design, expanded integration with hospital IT, and deepened OEM partnerships with system vendors.
Three-line SWOT: Strong reputation in blood management; Limited exposure to research-intensive segments; Opportunity—centralization of blood services and new hospital builds.
Notable Customers: American Red Cross Regional Centers, Large Health Systems, Specialty Clinics
9

Cryoport, Inc.

Logistics and technology company focused on temperature-controlled supply chain solutions for advanced therapies and clinical trials.

Key Financials: 2025 Bio Preservation revenue US$ 88.00 Million; recurring revenue share exceeds 65.00% of segment sales.
Flagship Products: Cryoport Express Shippers, Cryoportal Logistics Platform, Elite Transport Containers
2025-2026 Actions: Expanded global lane network, integrated enhanced real-time tracking, and signed multi-year logistics agreements with CGT sponsors.
Three-line SWOT: Deep specialization in CGT logistics; Highly exposed to therapy development cycles; Opportunity—commercial launches driving stable, long-term shipment volumes.
Notable Customers: Bristol Myers Squibb, Gilead, Global CRO Networks
10

Brooks Automation (Brooks Life Sciences / Azenta, Inc.)

Automation-centric company delivering robotic sample storage and informatics for advanced biobanking and pharma discovery.

Key Financials: 2025 Bio Preservation revenue US$ 82.00 Million; automation orders growing at 10.60% per year.
Flagship Products: Automated Sample Stores, SampleTrack Software, Biobank Management Systems
2025-2026 Actions: Scaled automation-as-a-service offerings, targeted national genomics programs, and expanded AI-enabled inventory analytics.
Three-line SWOT: Strong automation IP and software integration; Higher upfront cost versus manual systems; Opportunity—large genomic and precision-medicine biobanks.
Notable Customers: UK Biobank Partners, Top 10 Pharma Companies, Population Genomics Initiatives

SWOT Leaders

Thermo Fisher Scientific Inc.

SWOT Snapshot

SWOT
Strengths

Extensive global installed base, broad product portfolio across hardware and consumables, strong brand and service networks.

Weaknesses

Complex portfolio structure, premium pricing versus regional competitors, integration challenges after acquisitions.

Opportunities

Growth in cell and gene therapies, expansion of large national biobanking projects, increased demand for connected monitoring.

Threats

Price pressure from Asian manufacturers, regulatory shifts on energy efficiency, and supply-chain volatility for critical components.

Merck KGaA (MilliporeSigma)

SWOT Snapshot

SWOT
Strengths

Deep biochemical expertise, strong IP in preservation media, close relationships with bioprocessing and CGT customers.

Weaknesses

Limited ownership of core hardware platforms, dependency on third-party equipment ecosystems, complex global regulatory footprint.

Opportunities

Bundling reagents with single-use systems, supporting continuous bioprocessing, and expanding customized media offerings.

Threats

Intensifying competition from specialized media firms, potential raw-material constraints, and pricing scrutiny in mature markets.

Becton, Dickinson and Company (BD)

SWOT Snapshot

SWOT
Strengths

Unmatched reach in hospitals and labs, trusted sample-collection brand, strong regulatory and quality track record.

Weaknesses

Lower exposure to premium CGT and automated biobanking segments, slower innovation cadence in niche advanced areas.

Opportunities

Leveraging installed base to cross-sell advanced preservation solutions, rising test volumes, and centralization of lab networks.

Threats

Commoditization of basic consumables, hospital procurement consolidation, and competition from agile specialty suppliers.

Bio Preservation Market Regional Competitive Landscape

North America remains the largest Bio Preservation market, driven by dense networks of biobanks, academic centers, and cell therapy developers. Thermo Fisher Scientific Inc., BioLife Solutions, and Cryoport, Inc. are particularly strong, leveraging proximity to major CGT clusters. Funding for precision medicine and oncology trials sustains premium demand for advanced solutions.

Europe shows balanced growth, underpinned by national biobank programs, stringent data and quality regulations, and strong public healthcare. Merck KGaA (MilliporeSigma), PHC Holdings Corporation, and Brooks Automation secure share through compliance-centric offerings. EU sustainability and energy-efficiency policies encourage replacement of legacy freezers with newer, low-consumption systems from leading Bio Preservation market companies.

Asia Pacific is the fastest-growing region, propelled by China’s and India’s expanding clinical-trial infrastructure and rising investments in genomic medicine. Haier Biomedical Co., Ltd. and Thermo Fisher Scientific Inc. compete closely, with Haier benefiting from local manufacturing. Demand for mid-priced, IoT-enabled freezers and cryogenic systems is surging among hospitals, CROs, and regional biobanks.

Latin America witnesses gradual but steady adoption, anchored by reference laboratories, public blood banks, and international research collaborations. Chart Industries, Inc. and Helmer Scientific Inc. participate mainly in Tier-1 projects, often via distributors. Budget constraints favor cost-effective offerings, yet high-end equipment from established Bio Preservation market companies remains essential for flagship centers.

The Middle East and Africa present a fragmented yet rising opportunity, driven by new tertiary hospitals, vaccination programs, and donor-funded disease-surveillance labs. Haier Biomedical Co., Ltd. and BD compete with regional suppliers on price and reliability. High ambient temperatures amplify demand for robust, validated preservation systems and long-term service contracts.

In advanced economies across all regions, automation-led biobanking and population genomics initiatives accelerate adoption of robotics and software-centric solutions. Brooks Automation and Thermo Fisher Scientific Inc. are visible in these projects, integrating automated storage with informatics. Governments increasingly prefer proven Bio Preservation market companies that can deliver turnkey solutions and regulatory documentation.

Bio Preservation Market Emerging Challengers & Disruptive Start-Ups

Emerging Challengers & Disruptive Start-Ups

CryoNova Labs
Disruptor
USA

Develops next-generation vitrification-based preservation platforms designed to reduce ice crystal formation for sensitive cell and tissue samples.

FrostIQ Systems
Disruptor
Germany

Offers AI-driven freezer management software that predicts failures, optimizes energy use, and orchestrates inventory across multi-site biobanks.

CellGuard Biologics
Disruptor
United Kingdom

Provides serum-free, chemically defined cryopreservation media tailored for CAR-T and iPSC workflows, emphasizing regulatory-ready formulations.

ArcticPath Logistics
Disruptor
Canada

Specializes in sustainable, reusable cold-chain containers and route-optimization software for clinical trial and advanced therapy shipments.

BioSense ColdChain
Disruptor
India

Delivers low-cost IoT sensors and cloud dashboards enabling small labs and hospitals to monitor preservation equipment in real time.

NanoFreeze Technologies
Disruptor
Japan

Explores nanomaterial-enhanced cooling surfaces to achieve faster, more uniform freezing profiles for high-value biological samples.

Bio Preservation Market Future Outlook & Key Success Factors (2026-2032)

From 2025 to 2031, cumulative investments in metro expansions and station safety upgrades are projected to surpass significant amounts. The total market will scale from US$ 2.27 Billionin 2025 to US$ 3.38 Billion by 2031, reflecting a 6.90% CAGR. Winning Bio Preservation market companies will share several attributes. First, they will embed native IoT sensors, enabling predictive maintenance contracts that can double recurring revenue within five years. Second, modular design philosophies—interchangeable panels, plug-and-play controllers—will shorten installation windows and appeal to cost-sensitive public operators.

Localization strategies will also define competitive edges. Suppliers that establish regional assembly plants to meet content rules in India, Brazil, or the U.S. are likely to capture bonus points in tenders. Finally, sustainability credentials will move from optional to mandatory. Recyclable composite panels, energy-efficient brushless motors, and life-cycle carbon disclosures will become bid differentiators. In short, the coming decade rewards Bio Preservationmarket companies that marry digital intelligence with manufacturing agility and regulatory foresight.

Frequently Asked Questions

Find answers to common questions about this company report.